Hören Sie aufschlussreiche Diskussionen über Onkologie und Interviews mit Experten. Bleiben Sie informiert über Krebsversorgung, Behandlungen und Forschung.
Xichun Hu MD PhD; ESMO 2025: Antibody Drug Conjugate Trastuzumab Botidotin Outperforms Trastuzumab Emtansine in Patients with HER2-Positive Unresectable or Metastatic Breast Cancer
0 mins • Oct 28, 2025
Charts
This show is not currently ranked in any charts.
Neueste Folgen
Oct 28, 2025
Xichun Hu MD PhD; ESMO 2025: Antibody Drug Conjugate Trastuzumab Botidotin Outperforms Trastuzumab Emtansine in Patients with HER2-Positive Unresectable or Metastatic Breast Cancer
0 mins
Oct 27, 2025
Martin Wermke MD; ESMO 2025: Initial Therapy with Bi-Specific T-cell Engager Tarlatamab Promises Better Outcomes in Patients with Small Cell Lung Cancer
0 mins
Oct 24, 2025
John P. Crown MD MBA: ESMO 2025, Berlin: Adjuvant Ribociclib Brought Longer Freedom from Metastases for Patients with HR+/HER2- Early Breast Cancer: NATALEE Five Year Outcomes
0 mins
Oct 23, 2025
Javier C Cortés MD PhD: ESMO 2025, Berlin: Initial Therapy with Sacituzumab Govitecan Improves Progression-Free Survival in Patients with Newly-Diagnosed Metastatic Triple Negative Breast Cancer—ASCENT-03 study
0 mins
Oct 13, 2025
Trevor Leong MD: Operable Gastric or GE-Junction Adenocarcinoma: No Advantage from Neoadjuvant Radiotherapy
0 mins
Sprache
Englisch
Land
Vereinigtes Königreich
Website
Feed
Aktualisierung anfordern
Aktualisierungen können einige Minuten dauern.